US4496538A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
Assignee: Sanofi Vaccines US Inc
•
Filing: 1982-07-06
•
Granted: 1985-01-29
•
Expires: 2002-07-06
Abstract
Abstract A water-soluble covalent polysaccharide-diphtheria toxoid conjugate having a molecular weight between 140,000 and 4,500,000 dalton and a ribose/protein ratio between 0.25 and 0.75, capable of producing T-cell dependent antibody response to polysaccharide from H. influenzae b, prepared by mixing a derivatized diphtheria toxoid in a substantially cyanogen halide-free solution with a cyanogen halide-activated capsular H. influenzae b polysaccharide hapten consisting of approximately equal parts of ribose, ribitol and phosphate, which polysaccharide had previously been heat sized until more than 60% attained a molecular size between 200,000 and 2,000,000 dalton.
Inventors
- 👤 Lance K. Gordon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:29
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/02; A61K39/025; A61K39/0258; A61K39/102; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/16; A61K2039/60; A61K2039/6031; A61K2039/6037; Y; Y10; Y10S; Y10S424/00; Y10S424/831; Y10S530/00; Y10S530/806; Y10S530/807; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
96 words
A water-soluble covalent polysaccharide-diphtheria toxoid conjugate capable of producing T-cell dependent antibody response to polysaccharide from Haemophilus influenzae b, of molecular size above 140,000 and below 4,500,000 dalton, and of a ribose/protein ratio between 0.25 and 0.75, prepared by mixing adipic hydrazide derivatized diphtheria toxoid in a substantially cyanogen halide-free solution with a cyanogen halide activated capsular Haemophilus influenzae b polysaccharide consisting of approximately equal parts of ribose, ribitol and phosphate, which had previously been sized by heating until more than 60% of the polysaccharide was adjusted to a molecular size between 200,000 and 2,000,000 dalton.
Claim 2
Dependent Claim
96 words
A water-soluble covalent polysaccharide-diphtheria toxoid conjugate capable of producing T-cell dependent antibody response to polysaccharide from Haemophilus influenzae b, of molecular size above 140,000 and below 4,500,000 dalton, and of a ribose/protein ratio between 0.25 and 0.75, prepared by mixing adipic hydrazide derivatized diphtheria toxoid in a substantially cyanogen halide-free solution with a cyanogen halide activated capsular Haemophilus influenzae b polysaccharide consisting of approximately equal parts of ribose, ribitol and phosphate, which had previously been sized by heating until more than 60% of the polysaccharide was adjusted to a molecular size between 200,000 and 2,000,000 dalton.
Claim 3
Dependent Claim
11 words
A conjugate of claim 1, wherein said halide is the bromide.
Claim 4
Dependent Claim
116 words
A process for producing a water-soluble covalent polysaccharide-diphtheria toxoid conjugate capable of producing T-cell dependent antibody responsive to polysaccharide from Haemophilus influenzae b of molecular size between 140,000 and 4,500,000 dalton, and of a ribose/protein ratio between 0.25 and 0.75, which comprises (a) heating a capsular polysaccharide of Haemophilus influenzae b consisting of approximately equal parts of ribose, ribitol and phosphate until less than 20% is of a molecular size below 200,000 dalton and less than 20% is of a size above 2,000,000 dalton; (b) activation of the resulting sized polysaccharide with cyanogen bromide; (c) removal of substantially all the unreacted cyanogen bromide; and (d) agitation of the activated product with adipic hydrazide derivatized diphtheria toxoid.
Claim 5
Dependent Claim
116 words
A process for producing a water-soluble covalent polysaccharide-diphtheria toxoid conjugate capable of producing T-cell dependent antibody responsive to polysaccharide from Haemophilus influenzae b of molecular size between 140,000 and 4,500,000 dalton, and of a ribose/protein ratio between 0.25 and 0.75, which comprises (a) heating a capsular polysaccharide of Haemophilus influenzae b consisting of approximately equal parts of ribose, ribitol and phosphate until less than 20% is of a molecular size below 200,000 dalton and less than 20% is of a size above 2,000,000 dalton; (b) activation of the resulting sized polysaccharide with cyanogen bromide; (c) removal of substantially all the unreacted cyanogen bromide; and (d) agitation of the activated product with adipic hydrazide derivatized diphtheria toxoid.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-29 | 1988-07-30 | 1989-01-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-29 | 1992-07-30 | 1993-01-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-29 | 1996-07-30 | 1997-01-29 | $7700.00 | Window Closed / Lapsed |